Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015 (2015), Article ID 475630, 6 pages
http://dx.doi.org/10.1155/2015/475630
Clinical Study

Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson’s Disease

1Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain
2Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
3Epilepsy Unit, Department of Neurology, Hospital Clínic, Barcelona, Catalonia, Spain
4Neurology Service, Clínica Dexeus, Barcelona, Catalonia, Spain
5Neurology Service, Hospital de Terrassa, Barcelona, Catalonia, Spain
6Cap Clìnic de Neurologìa, Hospital Universitario Reus and Department of Medicine and Surgery, Universitat de Tarragona, Tarragona, Catalonia, Spain
7Neurology Service, Parc Sanitari Sant Joan de Déu, Sant Boi, Barcelona, Catalonia, Spain
8Neurology Service, Hospital Parc Taulí de Sabadell, Catalonia, Spain
9Clínica Juaneda, Palma de Mallorca, Balearic Islands, Spain

Received 4 August 2015; Accepted 30 September 2015

Academic Editor: Ivan Bodis-Wollner

Copyright © 2015 Francesc Vallderiola et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. B. Forsaa, J. P. Larsen, T. Wentzel-Larsen, K. Herlofson, and G. Alves, “Predictors and course of health-related quality of life in Parkinson's disease,” Movement Disorders, vol. 23, no. 10, pp. 1420–1427, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Videnovic and D. Golombek, “Circadian and sleep disorders in Parkinson's disease,” Experimental Neurology, vol. 243, pp. 45–56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. T. J. Swick, J. H. Friedman, K. R. Chaudhuri et al., “Associations between severity of motor function and nonmotor symptoms in Parkinson's disease: a post hoc analysis of the RECOVER study,” European Neurology, vol. 71, no. 3-4, pp. 140–147, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. K. R. Chaudhuri, “The dopaminergic basis of sleep dysfunction and non motor symptoms of Parkinson's disease: evidence from functional imaging,” Experimental Neurology, vol. 216, no. 2, pp. 247–248, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Giladi, A. Fichtner, W. Poewe, and B. Boroojerdi, “Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease,” Journal of Neural Transmission, vol. 117, no. 12, pp. 1395–1399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Trenkwalder, B. Kies, M. Rudzinska et al., “Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER),” Movement Disorders, vol. 26, no. 1, pp. 90–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Stocchi, P. Jenner, and J. A. Obeso, “When do levodopa motor fluctuations first appear in Parkinson's disease?” European Neurology, vol. 63, no. 5, pp. 257–266, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Barone, M. Amboni, C. Vitale, and V. Bonavita, “Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease,” Neurology, vol. 63, no. 8, pp. S35–S38, 2004. View at Google Scholar · View at Scopus
  9. M. Canesi, C. B. Mariani, I. U. Isaias, and G. Pezzoli, “Night-time use of rotigotine in advanced Parkinson's disease,” Functional Neurology, vol. 25, no. 4, pp. 201–204, 2010. View at Google Scholar · View at Scopus
  10. J.-P. Elshoff, M. Braun, J.-O. Andreas, M. Middle, and W. Cawello, “Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies,” Clinical Therapeutics, vol. 34, no. 4, pp. 966–978, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. European Medicines Agency, Neupro (Rotigotine): European Public Assessment Report—Summary of Product Characteristics, European Medicines Agency, 2014, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000626/WC500026397.pdf.
  12. K. Ray Chaudhuri, P. Martinez-Martin, A. Antonini et al., “Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER,” Parkinsonism and Related Disorders, vol. 19, no. 7, pp. 660–665, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, “Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases,” Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 3, pp. 181–184, 1992. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Trenkwalder, R. Kohnen, B. Högl et al., “Parkinson's disease sleep scale-validation of the revised version PDSS-2,” Movement Disorders, vol. 26, no. 4, pp. 644–652, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Peto, C. Jenkinson, and R. Fitzpatrick, “PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures,” Journal of Neurology, vol. 245, supplement 1, pp. S10–S14, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Antonini, L. Bernardi, D. Calandrella, F. Mancini, and M. Plebani, “Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders,” Functional Neurology, vol. 25, no. 1, pp. 21–25, 2010. View at Google Scholar · View at Scopus
  17. K. R. Chaudhuri, S. Pal, and C. Brefel-Courbon, “‘Sleep attacks’ or ‘unintended sleep episodes’ occur with dopamine agonists: is this a class effect?” Drug Safety, vol. 25, no. 7, pp. 473–483, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. P. E. O'Suilleabhain and R. B. Dewey Jr., “Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease,” Archives of Neurology, vol. 59, no. 6, pp. 986–989, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Fenu, J. Wardas, and M. Morelli, “Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease,” Behavioural Pharmacology, vol. 20, no. 5-6, pp. 363–379, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Voon, M. Sohr, A. E. Lang et al., “Impulse control disorders in parkinson disease: a multicenter case-control study,” Annals of Neurology, vol. 69, no. 6, pp. 986–996, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Trenkwalder, B. Kies, P. Dioszeghy et al., “Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson's disease: results from a 1-year, open-label extension of the RECOVER study,” Basal Ganglia, vol. 2, no. 2, pp. 79–85, 2012. View at Publisher · View at Google Scholar · View at Scopus